ATE277039T1 - Farnesyltransferase-inhibitoren die eine pyrrolstruktur haben und verfahren zu ihrer herstellung - Google Patents

Farnesyltransferase-inhibitoren die eine pyrrolstruktur haben und verfahren zu ihrer herstellung

Info

Publication number
ATE277039T1
ATE277039T1 AT00921128T AT00921128T ATE277039T1 AT E277039 T1 ATE277039 T1 AT E277039T1 AT 00921128 T AT00921128 T AT 00921128T AT 00921128 T AT00921128 T AT 00921128T AT E277039 T1 ATE277039 T1 AT E277039T1
Authority
AT
Austria
Prior art keywords
farnesyl transferase
production
transferase inhibitors
pyrrole structure
compound
Prior art date
Application number
AT00921128T
Other languages
English (en)
Inventor
Jong-Sung Koh
Hyun-Il Lee
You-Seung Shin
Hak-Joong Kim
Jin-Ho Lee
Jong-Hyun Kim
Hyun-Ho Chung
Shin-Wu Jeong
Tae-Saeng Choi
Jung-Kwon Yoo
Chung-Mi Kim
Kwi-Hwa Kim
Sun-Hwa Lee
Sang-Kyun Lee
Original Assignee
Lg Chem Investment Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-1999-0012994A external-priority patent/KR100384117B1/ko
Priority claimed from KR10-1999-0032814A external-priority patent/KR100384118B1/ko
Priority claimed from KR10-1999-0032972A external-priority patent/KR100395300B1/ko
Application filed by Lg Chem Investment Ltd filed Critical Lg Chem Investment Ltd
Application granted granted Critical
Publication of ATE277039T1 publication Critical patent/ATE277039T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00921128T 1999-04-13 2000-04-11 Farnesyltransferase-inhibitoren die eine pyrrolstruktur haben und verfahren zu ihrer herstellung ATE277039T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-1999-0012994A KR100384117B1 (ko) 1999-04-13 1999-04-13 피롤구조를 갖는 파네실 전이효소 억제제 및 그의 제조방법
KR10-1999-0032814A KR100384118B1 (ko) 1999-08-10 1999-08-10 피롤구조를 갖는 파네실 전이효소 억제제 및 그의 제조방법
KR10-1999-0032972A KR100395300B1 (ko) 1999-08-11 1999-08-11 피롤구조를 갖는 파네실 전이효소 억제제 및 그의 제조방법
PCT/KR2000/000334 WO2000064891A1 (en) 1999-04-13 2000-04-11 Farnesyl transferase inhibitors having a pyrrole structure and process for preparation thereof

Publications (1)

Publication Number Publication Date
ATE277039T1 true ATE277039T1 (de) 2004-10-15

Family

ID=27349937

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00921128T ATE277039T1 (de) 1999-04-13 2000-04-11 Farnesyltransferase-inhibitoren die eine pyrrolstruktur haben und verfahren zu ihrer herstellung

Country Status (8)

Country Link
US (1) US6511978B1 (de)
EP (1) EP1169320B1 (de)
JP (1) JP2002543074A (de)
CN (1) CN1151148C (de)
AT (1) ATE277039T1 (de)
AU (1) AU4147500A (de)
DE (1) DE60014053D1 (de)
WO (1) WO2000064891A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100384117B1 (ko) * 1999-04-13 2003-05-14 주식회사 엘지생명과학 피롤구조를 갖는 파네실 전이효소 억제제 및 그의 제조방법
KR20010063274A (ko) * 1999-12-22 2001-07-09 성재갑 〔1-｛〔1-（1,3-벤조디옥솔-5-일메틸-1ｈ-이미다졸-5-일〕메틸｝-4-(1-나프틸)-1ｈ-피롤-3-일〕（4-메틸-1-피페라지닐）메타논의 약학적 조성물
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507590A (ja) * 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
CA2249615A1 (en) * 1996-04-03 1997-10-09 Robert Gomez Inhibitors of farnesyl-protein transferase
ID24175A (id) * 1997-11-28 2000-07-13 Lg Chemical Ltd Turunan-turunan imidazol yang mempunyai aktivitas penghambatan untuk farnesil transferase dan proses pembuatannya
ES2185307T3 (es) * 1998-02-02 2003-04-16 Lg Chemical Ltd Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion.

Also Published As

Publication number Publication date
JP2002543074A (ja) 2002-12-17
EP1169320B1 (de) 2004-09-22
EP1169320A1 (de) 2002-01-09
WO2000064891A1 (en) 2000-11-02
US6511978B1 (en) 2003-01-28
CN1346353A (zh) 2002-04-24
CN1151148C (zh) 2004-05-26
EP1169320A4 (de) 2002-10-30
AU4147500A (en) 2000-11-10
DE60014053D1 (de) 2004-10-28

Similar Documents

Publication Publication Date Title
DE60014053D1 (de) Farnesyltransferase-inhibitoren die eine pyrrolstruktur haben und verfahren zu ihrer herstellung
ATE229017T1 (de) Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
GEP20022678B (en) Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors, their Pharmaceutical compositions and methods for Treatment
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
BRPI0108664B8 (pt) composto, composição farmacêutica e uso de um composto
AU6434600A (en) Biphenyl derivatives, production thereof and use as medicines
MX2007007458A (es) Derivados de quinazolina para inhibir crecimiento de celulas cancerigenas y metodo para la preparacion de los mismos.
BRPI0408727A (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar de uma condição ou estado de doença mediados pela atividade da quinase p38 ou mediados pelas citocinas produzidas pela atividade da quinase p38, e, uso de um composto
EP1678162A4 (de) P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält
NO20013060D0 (no) Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff
WO2001027110A3 (de) Am sechsring substituierte, bicyclische imidazo-3-yl-aminderivate
NO20002548L (no) Nye substituerte dimere forbindelser, en fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger som inneholder dem
WO2001000617A3 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same
DE69734678D1 (de) 6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung
ECSP003680A (es) Proceso para derivados del acido fenilacetico
WO2001085095A3 (en) Chiral fluoroquinolizinone arginine salt forms
ATE307809T1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
ATE214051T1 (de) Substituierte tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
MY133230A (en) Combination of no synthase inhibitor(s) and metabolic antioxidant(s)
DK0764169T3 (da) Lægemiddelsalte
WO2000046193A3 (en) Ether derivatives having neuronal activity
BR0009795A (pt) Processo para a ppeparação de um composto da fórmula (i), e, composto
WO2004000206A3 (en) Pyrazole-3-one derivative, method for preparing the same, and pharmaceutical composition containing the same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties